In the realm of intellectual property, one of the most prevalent misconceptions is the belief that owning a patent equates to the freedom to commercialize a product. This assumption, particularly within Indian patent law, is fraught with risk. While a patent provides the holder with an exclusionary right to prevent others from exploiting the invention, it does not inherently grant the right to practice the invention without infringing on prior or broader third-party rights.
This nuanced distinction underscores the importance of a thorough freedom-to-operate (FTO) assessment, a critical component of intellectual property strategy that is often overlooked. An FTO assessment evaluates whether a product or process can be developed, used, sold, or imported in a specific jurisdiction without violating the valid patent rights of others. Essentially, it acts as a legal risk assessment that determines the viability of market entry, scaling, and investment without the threat of infringement litigation.
The Indian context of this analysis is primarily influenced by Section 48 of the Patents Act, 1970, as well as judicial interpretations concerning claim construction, infringement, and validity. This article proposes five key points:
- A patent is a right to exclude others, not an automatic right to practice one’s invention.
- Patentability and freedom to operate are separate legal and commercial considerations.
- FTO is essentially a forecast of how courts might interpret patent claims and assess infringement.
- Regulatory approval does not equate to patent clearance.
- The true value of FTO lies in pre-market entry mitigation.
The Misleading Nature of Patent Ownership
A common misconception in intellectual property law is the statement, “We have a patent, so we are protected.” This notion is only partially true. Under Section 48 of the Patents Act, 1970, a patent grants the patentee the exclusive right to prevent others from making, using, offering for sale, selling, or importing the patented invention in India. However, it does not provide affirmative permission to commercialize one’s product without infringing third-party rights. This is crucial because innovation often builds on existing patents, and a company may hold a valid patent for an improvement, yet still infringe on an earlier patent owned by another entity.
An FTO assessment addresses this potential exposure, differentiating between a product launch with manageable legal risk and one susceptible to cease-and-desist notices or injunctions just before launch, after significant commercial investments have been made. Thus, a patent should be viewed more as a sword rather than a shield; freedom to operate is the shield, constructed separately.
Practical Considerations for FTO
An FTO assessment poses a practical question: Can a product or process be legally developed, used, sold, or imported in the desired jurisdictions without infringing valid third-party patent rights?
Each aspect of this question has legal implications. The activities listed reflect the exclusive rights under Section 48, wherein liability may arise from any of these acts. The term “relevant jurisdictions” pertains to the territorial nature of patent rights, as these are national rights and clearance in one country does not imply clearance elsewhere. “Valid and enforceable” patents exclude expired, lapsed, or revoked patents. Notably, an FTO is a professional legal opinion and risk assessment, not a court ruling. Infringement disputes ultimately fall under judicial purview. FTO focuses on third-party rights; a company’s own patents do not guarantee freedom to operate.
Differences Between Patentability and Freedom to Operate
Patentability and freedom to operate are distinct legal inquiries. Patentability evaluates whether an invention meets statutory requirements such as novelty and inventive step, determined by the Patent Office. Freedom to operate, however, assesses whether commercial exploitation would infringe enforceable third-party rights, a conclusion often reached through legal analysis and court decisions.
More Read
The outcomes of these inquiries can diverge. A product may be patentable yet still infringe an existing patent, or conversely, a product may be unpatentable but commercializable if it is in the public domain. The grant of a patent answers the question of protection availability, but not the safety of commercialization.
Indian Courts and Patent Infringement
FTO analysis must consider how Indian courts interpret infringement. As established in Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries Ltd., (1979) 2 SCC 511, patent validity and scope are assessed with reference to the claims, aided by the specification but not expanded beyond the claim language. Courts examine whether essential claim elements are present in the allegedly infringing product or process, requiring structured claim-by-claim mapping against the proposed product.
In Raj Prakash v. Mangat Ram Choudhary, AIR 1978 Del 1, the Delhi High Court applied the “pith and marrow” approach, recognizing infringement when the invention’s substance is taken despite minor variations. While Indian law does not strictly follow the US doctrine of equivalents, purposive construction is applied to prevent evasion through immaterial changes.
Key Risks in FTO Assessments
- Granted and In-Force Patents: Only active patents pose a risk; expired or lapsed patents do not.
- Pending Applications: Published applications under Section 11A may change during prosecution, with provisional rights from publication date, but infringement proceedings can only begin post-grant.
- Territoriality: Patent rights are territorial; supply chain considerations determine risk geography.
- Claim Scope: Infringement risk is defined by claim elements, not titles or abstracts.
- Validity Risk: A potentially invalid patent under Section 64 presents different risks compared to a robust one.
Regulatory Approval vs. Patent Clearance
Regulatory approval should not be confused with patent clearance. Approvals from bodies like the Central Drugs Standard Control Organisation address safety and efficacy but do not consider patent rights. India does not follow a patent linkage system that mandates regulatory patent status checks, as affirmed in Bayer Corporation v. Union of India & Ors. (Delhi High Court, 2009). A product may be fully approved yet infringe on valid patents upon launch.
The Mitigation Toolkit
FTO is valuable for its mitigation potential:
- Design-Around: Early modification to avoid claim elements is often effective.
- Licensing: Licensing may be commercially viable when risk is unavoidable.
- Validity Challenges: Options include pre-grant opposition (Section 25(1)), post-grant opposition (Section 25(2)), and revocation (Section 64).
- Waiting for Expiry: Patent term in India is 20 years from filing (Section 53).
- Geographic Structuring: Organizing operations in jurisdictions without patents.
- Section 105 Declaratory Relief: Allows seeking declaration of non-infringement after patentee refuses or fails to respond to a written acknowledgment request.
The Commercial Importance of FTO
FTO holds substantial commercial relevance:
- Investment and M&A: IP portfolios and infringement risk are key evaluation factors for investors.
- Litigation Risk Management: A contemporaneous FTO opinion can demonstrate good faith, though it is not conclusive regarding liability.
- Corporate Governance: Board approvals based solely on patent ownership depict incomplete analysis; FTO-informed decisions reflect thorough diligence.
Conclusion
A patent is not a commercial clearance document but a right to exclude others. It does not ensure the freedom to operate. While this distinction is clear in doctrine, it is commercially crucial in practice. FTO analysis bridges this doctrinal understanding with business reality, offering strategic options if conducted early, and risk containment if done late.
For businesses entering or expanding in India, the critical question is not patent ownership but whether they possess the freedom to operate. Can the product be sold and sustained in the market? A patent alone cannot answer that question.
About the Authors: Lucy Rana is the Managing Partner of S.S. Rana & Co. Huda Jafri is an Associate at the firm.
Disclaimer: The opinions expressed are those of the author and do not necessarily reflect the views of Bar & Bench. For publication of Deals, Columns, or Press Releases on Bar & Bench, please fill out the form available here.
